Right drug, right dose — pre-emptively.
Adverse drug reactions and trial-and-error dosing are avoidable when genotype is known before the prescription is written. Test once, use for life.
Six properties that make it work.
Test once, use for life
Cost amortises across every subsequent prescription the patient ever receives.
Deterministic mapping
Diplotype to phenotype to guidance runs through versioned consortium tables. No inference in the path.
Concrete action
A dose adjustment or an alternative agent — not a risk score to interpret.
Measurable benefit
Avoided adverse events are the strongest procurement argument available.
Established guidelines
CPIC-aligned mappings provide a defensible, citable evidence base.
Cross-module value
Applies in diabetes, oncology, cardiology and psychiatry alike.
From diplotype to dosing guidance.
From the molecular layer, with assay limitations recorded explicitly rather than assumed away.
Deterministic mapping using versioned consortium tables — the language model is not in this path.
Guidance appears at the moment the drug is chosen, not in a report the prescriber may never open.
Drug–drug, drug–gene and drug–nutrient, because in chronic disease they co-occur.
A genotype tested once is reused at every prescribing event for the rest of the patient’s life.
Interoperable with what you already run.
Bring pharmacogenomics to your service.
Anchor sites get early capability and a real say in the roadmap.